1. Home
  2. SLNO vs MQ Comparison

SLNO vs MQ Comparison

Compare SLNO & MQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNO
  • MQ
  • Stock Information
  • Founded
  • SLNO 1999
  • MQ 2010
  • Country
  • SLNO United States
  • MQ United States
  • Employees
  • SLNO N/A
  • MQ N/A
  • Industry
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • MQ Computer Software: Prepackaged Software
  • Sector
  • SLNO Health Care
  • MQ Technology
  • Exchange
  • SLNO Nasdaq
  • MQ Nasdaq
  • Market Cap
  • SLNO 2.3B
  • MQ 1.9B
  • IPO Year
  • SLNO 2014
  • MQ 2021
  • Fundamental
  • Price
  • SLNO $71.99
  • MQ $4.19
  • Analyst Decision
  • SLNO Strong Buy
  • MQ Hold
  • Analyst Count
  • SLNO 8
  • MQ 14
  • Target Price
  • SLNO $92.00
  • MQ $5.14
  • AVG Volume (30 Days)
  • SLNO 1.8M
  • MQ 8.5M
  • Earning Date
  • SLNO 05-08-2025
  • MQ 05-07-2025
  • Dividend Yield
  • SLNO N/A
  • MQ N/A
  • EPS Growth
  • SLNO N/A
  • MQ N/A
  • EPS
  • SLNO N/A
  • MQ 0.05
  • Revenue
  • SLNO N/A
  • MQ $506,995,000.00
  • Revenue This Year
  • SLNO N/A
  • MQ $20.89
  • Revenue Next Year
  • SLNO N/A
  • MQ $21.23
  • P/E Ratio
  • SLNO N/A
  • MQ $79.67
  • Revenue Growth
  • SLNO N/A
  • MQ N/A
  • 52 Week Low
  • SLNO $36.61
  • MQ $3.37
  • 52 Week High
  • SLNO $73.97
  • MQ $6.25
  • Technical
  • Relative Strength Index (RSI)
  • SLNO 84.44
  • MQ 50.82
  • Support Level
  • SLNO $48.29
  • MQ $4.36
  • Resistance Level
  • SLNO $51.88
  • MQ $4.59
  • Average True Range (ATR)
  • SLNO 3.03
  • MQ 0.19
  • MACD
  • SLNO 2.32
  • MQ -0.01
  • Stochastic Oscillator
  • SLNO 93.61
  • MQ 45.97

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

About MQ Marqeta Inc.

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

Share on Social Networks: